Copyright
©2014 Baishideng Publishing Group Inc.
World J Clin Oncol. Oct 10, 2014; 5(4): 621-632
Published online Oct 10, 2014. doi: 10.5306/wjco.v5.i4.621
Published online Oct 10, 2014. doi: 10.5306/wjco.v5.i4.621
Figure 3 C4.
4A in pulmonary adenocarcinoma. Panels A-E: C4.4A expression as detected by immunohistochemistry with a polyclonal antibody in normal alveoli (A; reproduced with permission from Jacobsen et al[34], 2012), atypical adenomatous hyperplasia (B), invasive AC with predominant mucinous lepidic (C), non-mucinous lepidic (D), acinar (E), papillary (F) and solid (G) pattern. Panel H: Kaplan-Meier estimates for the survival of AC patients, which is correlated with C4.4A scores, here stratified by tertiles (red: Lowest level of C4.4A; blue: Intermediate level of C4.4A; green: Highest level of C4.4A). Modified from Jacobsen et al[33], 2013.
- Citation: Jacobsen B, Kriegbaum MC, Santoni-Rugiu E, Ploug M. C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma. World J Clin Oncol 2014; 5(4): 621-632
- URL: https://www.wjgnet.com/2218-4333/full/v5/i4/621.htm
- DOI: https://dx.doi.org/10.5306/wjco.v5.i4.621